Lyka Labs share news, announcements and annual reports
NSE: LYKALABSBSE: 500259Pharmaceuticals & BiotechnologySmall Cap
Lyka Labs Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jun 1986 on BSE, Feb 1995 on NSE
Last close ₹76.60up ₹0.35 (0.46%)BSE ₹77.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹76.25.
30 Oct: open ₹77.77, high ₹77.77, low ₹76.60
52-week range of traded prices to 30 Oct 2026
₹44.10Low, 30 Mar 2026₹98.25High, 31 Oct 2025
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹277 Cr2,310th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.89
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −4.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −3.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.47
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 6,475
Lyka Labs disputes and clarifications
44 filed, newest first.
Jun 2026
11 Jun · Legal
11 Jun · Legal
Significant movement in price has been observed in Lyka Labs Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.11 Jun · Legal
Clarification sought from Lyka Labs Ltd
Apr 2026
9 Apr · Legal
9 Apr · Legal
The exchange asked on 8 Apr 2026
8 Apr · Legal
Clarification Sought from Lyka Labs Ltd
May 2025
8 May · Legal
8 May · Legal
Feb 2025
27 Feb · Legal
Sep 2024
12 Sep · Legal
Exchange has sought clarification from Lyka Labs Limited for the quarter ended 30-Jun-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Jun 2023
8 Jun · Legal
Exchange has sought clarification from Lyka Labs Limited for the quarter ended 31-Mar-2023 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone auditors report not submitted. The response of the Company is awaited.
Aug 2022
29 Aug · Legal
Clarification sought from Lyka Labs Ltd26 Aug · Legal
The exchange asked on 26 Aug 2022
25 Aug · Legal
The exchange asked on 24 Aug 2022
11 Aug · Legal
Exchange has sought clarification from Lyka Labs Limited with respect to announcement dated 09-Aug-2022 informing about Appointment of Director.On the basis of aforesaid announcement, the Company is required to provide/clarify the following: 1. Disclosure of relationships between directors (in case of appointment of a directors) 2. Brief profile (in case of appointment) 3. Confirmation from Director that there are no material reasons for resignation other than that disclosed 4. Affirmation that the Director being appointed is not debarred from holding the office of director by virtue of any SEBI order or any other such authority The response of the company is awaited.
Apr 2022
12 Apr · Legal
The exchange asked on 11 Apr 2022
11 Apr · Legal
Clarification sought from Lyka Labs Ltd
Nov 2021
1 Nov · Legal
Exchange has sought clarification from Lyka Labs Limited with respect to announcement dated 29-Oct-2021, regarding merger of Lyka Exports Limited with Lyka Labs Limited. On basis of above the Company is required to clarify following: 1. Brief details of change in shareholding pattern (if any) of listed entity;2. Name of the entity (ies) forming part of the amalgamation/merger, details in brief such as, size, turnover etc.;3. Whether the transaction would fall within related party transactions? If yes, whether the same is done at arm's length;4. Area of business of the entity (ies);5. Rationale for amalgamation/ merger;6. In case of cash consideration amount or otherwise share entitlement/exchange ratio.The response of the Company is awaited.
Jun 2021
3 Jun · Legal
Exchange has sought clarification from Lyka Labs Limited with respect to manufacture and market of Liposomal Amphotericin B Injection.On basis of above the Company is required to clarify following:1. Date of launch;2. Whether caters to domestic/ international market;3. Name of the countries in which the product is launched (in case of international).The response of the Company is awaited.
Sep 2020
Jul 2020
15 Jul · Legal
Exchange has sought clarification from Lyka Labs Limited for the quarter ended 31-Mar-2020 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange. The response of the Company is awaited.
Apr 2020
8 Apr · Legal
Clarification sought from Lyka Labs Ltd7 Apr · Legal
The exchange asked on 7 Apr 2020
Feb 2020
Dec 2019
20 Dec · Legal
The exchange asked on 19 Dec 2019
19 Dec · Legal
Clarification sought from Lyka Labs Ltd
Aug 2019
19 Aug · Legal
Exchange has sought clarification from Lyka Labs Limited for the quarter ended 30-Jun-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Apr 2019
9 Apr · Legal
Exchange has sought clarification from Lyka Labs Limited with respect to announcement dated 30-Mar-2019, regarding " Lyka Labs Limited has informed the Exchange regarding 'One Time Settlement- Pursuant to regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Company's account was classified as Non-Performing Asset by Bank of Maharashtra ( The Bank) with effect from 1st May, 2016. The outstanding amount payable to the Bank as on 30th September, 2018 was Rs. 16.46 crores.Thereafter, the Company entered into One Time Settlement with the Bank and arranged to make upfront payment of Rs. 11.00 Crores as settlement amount and Rs. 6.49 lakh (including GST of Rs. 0.99 lakh) as processing fees to the Bank pursuant to which the Bank has released its mortgage charge on the immovable property of the Company situated at Gala No. 101 to 108 and 150 to 154, Shiv Shakti Industrial Estate, M V Road, Marol, Andheri (East), Mumbai 400059 and is also in the process of partly releasing the pledged shares held by the Promoters of the Company.Further, an amount of Rs. 33 lakhs being the interest for delayed period along with revalidation fees amounting to Rs.2.75 lakhs + GST is payable to the Bank by 30th April 2019 and on payment of said amount the Bank will release the pending pledged shares held by the Promoters of the Company.This is for your information and record.'.". On basis of above the Company is required to clarify following: 1. Brief summary of the OTS 2. Reasons for opting for OTS; The response of the Company is awaited.4 Apr · Legal
The exchange asked on 3 Apr 2019
3 Apr · Legal
Clarification Sought on Price Movement
Oct 2015
21 Oct · Legal
Clarification sought from Lyka Labs Ltd